Dosecann to add 32 new jobs within next two years

Dosecann CEO Greg Boone (Photo courtesy of CBC)

Emergence client Dosecann, a cannabis oil extraction company in Charlottetown, has plans to add 32 new employees over the next two years which will more than double their team. The PEI Government will offer them labour rebates to support this expansion. CEO Greg Boone says it will allow them to ramp up their team more quickly and be ready with a well-trained team when they enter the production phase.

To read press coverage, please see links below:

Government of PEI news story here:

“It is with great pride that Dosecann calls Charlottetown, PEI, home and the support that we have received from the Province has been instrumental to our success to date. We would like to sincerely thank the Province, Innovation PEI and Skills PEI who have supported our dream of building a world class cannabis company and, on a personal note, for making me feel like an ‘honorary Islander’.”  (CEO Greg Boone)

CBC News story here:

“It probably allows us to bring new people on more quickly,” said Greg Boone, chief executive officer of Dosecann. “And what that does is it really allows us to train them properly, orient them properly and get them up to speed more quickly so that when we go into production, they know exactly what’s happening and what’s going on and where they are supposed to be.”

Dosecann is a Canadian cannabis company dedicated to developing Cannabis Solutions for the global cannabis industry. Proudly located in Charlottetown, PEI, Dosecann has assembled a world-class team housed in a purpose-built, 42,000 sqft GMP compliant facility that will be the hub for cannabis extraction, product innovation and formulation, R&D, quality testing and manufacturing.

Posted in Clients

Emergence client, SomaDetect, secures investment from DFA

Companies around the globe are leveraging innovative technologies and artificial intelligence to make more informed decisions and better run their businesses..

Recently, Dairy Farmers of America (DFA), a national cooperative owned by dairy farm families across the U.S., announced an investment in Emergence client, SomaDetect, a dairy technology startup that will help farmers utilize artificial intelligence to more closely monitor the health of their herd and improve milk quality.

SomaDetect is a dairy technology startup that uses real-time analytics to improve milk quality.

“This is a potentially game-changing technology for our farmers and the industry as it allows dairy farmers to know the health of each cow and quality of milk in real time. With access to better data, our farmers can make more knowledgeable decisions, which is a huge value.”

David Darr, president, farm services at DFA
SomaDetect CEO, Bethany Deshpande, presents at the 2017 Ag Innovation Challenge in Missouri

With SomaDetect’s technology, farmers can easily evaluate components of interest in raw milk, including fat, protein, somatic cells, progesterone and trace antibiotics.

While the technology continues to be refined for commercialization, the platform provides cost-effective, instant analysis, which enables farmers to make rapid and proactive decisions related to the overall health and management of their cows.

SomaDetect recently completed the 2018 Sprint Accelerator program, which is also sponsored by DFA. The Accelerator is a 90-day, immersive program that helps accelerate and grow startup businesses.

SomaDetect CEO, Bethany Deshpande

“DFA and their members have been a great mentor and partner for us, and we’re excited to continue working with them to help bring the SomaDetect platform to dairy farmers across the country.

Dairy farmers have been our greatest teachers and allies throughout the development of our company and technology, and our goal is to show them the same care they show their herd.”

Bethany Deshpande, Founder and CEO at SomaDetect
Posted in Clients

Emergence client, Advanced Extraction Systems, unveils the Largest CO2 Supercritical Fluid Extraction System for the Global Hemp & Cannabis Industries

Emergence client, Charlottetown, PEI-based Advanced Extraction Systems Inc. (AESI), has announced their latest innovation: the highest throughput CO2 extraction system for the global cannabis and hemp markets.  

AESI has designed and engineered a 2X1000L, expandable to 4X1000L, supercritical CO2fluid extraction system capable of processing approximately 4,500kg of dried biomass per day which translates to over 1.6 Million kilograms per annum. Actual yield is based on initial biomass potency. 

“Keeping up with our customers aggressive growth plans has to be at the forefront of our research and development goals. We design our equipment to be modular and expandable to scale up with our customers future capacity requirements.”  

David Campbell, AESI Co-Founder & COO

Nick Desroches, Engineering Manager for AESI told usI, “Coriolis mass-flow meters are standard equipment on every system in our impressive and growing product line.Our newest 2X1000L system demonstrates a ground-breaking 100kg/minute flow-rate which is verified by the Coriolis mass-flow meter.” 

We are very excited to see the Hemp Industry opening up after the passing of the 2019 Farm Bill in the United States.  To date, an industry wide concern for Licensed Producers has been sourcing industrial scale CO2 extraction equipment with the ability to process tons of biomass. Our latest development is the perfect solution with impressive throughput numbers that will help ensure producers can grow their businesses to new heights.”

David Campbell, AESI Co-Founder & COO

In November 2018, AESI won the Emerging Business Award from the Greater Charlottetown Area Chamber of Commerce after demonstrating remarkable growth, innovation, and industry leadership. 

AESI continues to be a pioneer in this emerging industry as their latest development will assist Licensed Producers in meeting demand for oil and CBD related products.

About Advanced Extraction Systems Inc.

AESI designs, engineers and fabricates supercritical fluid CO2 extraction systems with a specific focus in the medical/recreational marijuana and hemp industries. AESI has assembled a skilled management team and a world-class scientific advisory group with over 75 years of experience in supercritical fluid design and processes.  AESI offers the cleanest, most advanced CO2 extraction processes that are leading edge due to the companies ongoing internal focus on research and development. AESI CO2 extraction systems are unique in design, efficiency, and ease of operation. Specifically, AESI systems can be differentiated from the competition in 6 key technical areas; better pump reliability, superior flow rates, superior fractionation, more phase management control, cGMP recipe development, and scalability for future growth.

For further information: David Campbell, Chief Executive Officer, Advanced Extraction Systems Inc.,, 1-877-396-8801,

Posted in Uncategorized

New Licensing Deal for Emergence Client, Simini Technologies

“Pets are part of the family” is a common refrain in the pet and vet industries, but two companies are taking that to heart to help people and their aging pets gain a new lease on life.  

Through connections made at the 2018 Annual Animal Health Homecoming, a new licensing deal was conceived for two young companies aiming to improve both by leveraging the One Health Initiative mindset.  

Motega Health Inc., a biopharmaceutical and food company bringing novel, patented technologies to pharmaceutical and food sciences for human and animal health products, today announced it has executed a licensing agreement with Emergence client, Simini Technologies, Inc., a pharmaceutical company which specializes in licensing veterinary rights to human health drug candidates to develop those products for animal applications.  

 “Motega Health and their world-class team bring a novel approach to active molecules creating diverse products to meet many needs.  Collaborating with Motega has allowed Simini to accelerate a new solution to meet the challenge of muscle loss in aging pets and those with osteoarthritis.” 

Under the terms of the licensing agreement, Motega Health will provide Simini with a North American royalty-bearing license to research, develop, and commercialize a novel therapy for companion animals. Simini will be responsible for all further research and commercial activities under the licensing agreement. Motega Health is eligible for additional undisclosed commercial milestone payments. 

“We are very pleased to be partnering with Simini and their team and are excited by the energy and creative thinking they are bringing to the commercial process in veterinary medicine.”  

Dr. Blake Hawley, CEO of Motega Health

About Simini Technologies, Inc. 

Simini Technologies Inc. is a specialized pharmaceutical company that licenses veterinary rights to human health drug candidates to develop those products for animal applications.   The Company has assembled a robust pipeline of commercialization and development candidates targeting significant animal health conditions including atopic dermatitis, osteoarthritis, aging and infection control.  Learn more about Simini Technologies at

About Motega Health Inc.

Motega Health is a biopharmaceutical company dedicated to the discovery, development and licensing of next-generation multifunctional biotherapeutics and commercialization of pharmaceutical, hormone, OTC products, nutraceuticals, foods, and beverages. Motega Health’ suite of complementary therapeutic platforms and its fully-integrated innovation engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Motega Health is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in eight therapeutic areas. In addition to Motega Health’s pipeline, it is seeking multiple strategic partnerships with global biopharmaceutical and fast-moving consumer goods companies.

Posted in Uncategorized

Emergence client, Somru Bioscience, is hiring…

Emergence client, Somru Bioscience Inc. is hiring…

Somru is actively seeking applications from qualified candidates for an R&D Biosimilar Manufacturing Manager.

Somru is an emerging biotechnology company dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications.

The company utilizes a unique and proprietary Somru™ technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays in a short period of time.

They also offer a wide range of quality reagents for research and diagnostics applications as well as for biosimilar research and development.

Posted in Clients

“Supply Chain 1-2-3”: for Food & Beverage Businesses in Atlantic Canada

Supply Chain 1-2-3 is a learning and development program to support growth-oriented companies. This program will help you learn how to sell more in existing channels or expand your reach to new channels.

Gain the knowledge, skills and tools you need to help your business compete.

Registration now open to Food & Beverage Businesses in Atlantic Canada 

Are you an Atlantic Canadian Food & Beverage business in growth mode? Are you looking to sell more in existing channels or expand your reach into new channels?  

If you answered “yes” to the two previous questions you may register now for Supply Chain 1-2-3.

The program combines 5 in-classroom workshops, 2 virtual webinars, and a final session where you will put your new knowledge and skills to work in a simulated Meet the Buyer event. Learn more about the topics that will be covered by experts like Peter Chapman from SKUFood and other experienced facilitators. 

Space is limited! Click the button below to register now for Supply Chain 1-2-3.

Register for Supply Chain 1-2-3

Registration Instructions

Workshop Locations and Schedules across Atlantic Canada

Halifax, NS:

Workshops scheduled on Tuesdays, from March 5th, 2019 – to April 23rd, 2019.

Location: Future Inns Halifax Hotel & Conference Centre, 30 Fairfax Drive, Halifax, NS

St. John’s, NL:

Workshops scheduled on Thursdays, from March 7th, 2019 – to April 25th, 2019.

Location: Sheraton Hotel Newfoundland, 115 Cavendish Square, St.John’s, NL

Moncton/Fredericton, NB*:

Workshops scheduled on Tuesdays, from March 19th, 2019 – to May 7th, 2019*In-classroom workshops alternate between Moncton & Fredericton.

Charlottetown, PEI:

Workshops scheduled on Thursdays, from March 21st, 2019 – to May 9th, 2019.

Location: Charlottetown Inn, 238 Grafton Street, Charlottetown, PEI

Please note that it is possible to split the workshops between multiple employees to provide you with more flexibility. In addition to group workshops, up to 4 hours of individual professional coaching and consulting is available as part of the program to help you apply the new skills and knowledge. 

What is the investment for participating SMEs?

  • Complete an online learning needs assessment (approx. 1 hour)
  • Participate in a series of 8 interactive workshops delivered by expert facilitators
  • Complete a post-program online evaluation (approx. 1 hour) and provide testimonial information (on a volunteer basis).
  • Thanks to investments from our governments, there is no cost for you to participate in this program. Your only investment will be the commitment of your time. 

Questions? Email or call 1 (877) 644-2267 to learn more about Supply Chain 1-2-3. 

Posted in Uncategorized

Emergence client, Stepscan Technologies Inc., launches new mobility assessment tool

Emergence client, Charlottetown, PEI-based Stepscan Technologies Inc. has announced a new mobility assessment tool for assessing hospital patients and nursing home residents for accidental falls.

Stepscan® is a pressure sensitive electronic floor tile system and software for analyzing gait and balance.

Stepscan’s new mobility assessment tool specifically addresses the growing problem of accidental falls in hospitals and Long-Term Care facilities.

Accidental falls in hospitals and nursing homes is a widespread and serious threat to patient safety. 

The Centers for Disease Control and Prevention (CDC) estimates that between 50-75% of elder patients suffer from a nursing home fall each year and that 1,800 elderly patients die each year as a result. Falls among patients and /or residents in a typical nursing home (100 beds) is reported to be 100-200 falls per year.

StepScan CEO, Crystal Trevors with Emergence director, Martin Yuill

The statistics for hospital falls are similar.  There are significant incremental costs associated with falls including patient care costs, increased length of stay and liability.  The direct cost to the US healthcare industry due to accidental falls in nursing homes and hospitals is estimated to be in the range of $27 billion.

Stepscan® gait and balance technology is currently being used in hospitals and clinics internationally in applications ranging from general rehabilitation, pre-surgery planning and post-operative assessment of Cerebral Palsy children, stroke rehabilitation, concussion screening and fitting of prosthetic limbs. 

“Last year we were approached by the Director of Care of a long term care facility in Canada with a request to develop a specific fall risk assessment software report that could be used as part of a fall risk screening and monitoring process in their facility,” Crystal Trevors, Stepscan Technologies owner and founder, told us.

“The resulting Stepscan mobility assessment tool is capable of measuring and tracking irregularities in gait and balance, easily and quickly identifying residents or hospitalized patients who are at high risk for falling. Stepscan also presents a screening and monitoring tool that demonstrates duty of care in ensuring patient and resident safety and well-being.   I am confident that Stepscan will be a valuable addition to any fall prevention and monitoring programs any organization currently has in place”.

Stepscan Technologies Inc. is a federally incorporated Canadian technology company dedicated to the development and commercialization of its multiple patents in the field of movement tracking and analysis. The company’s pressure sensitive flooring system has many applications beyond medical research and clinical rehabilitation, including sports training, clinical drug trials, military training /virtual simulation, and security. Stepscan Technologies is one of over 45 companies that make up the Prince Edward Island Bioscience Cluster and they are a proud member of the Atlantic Canada Aerospace and Defense Association (ACADA).

Posted in Uncategorized

Emergence clients are invited to Competitive Intelligence training

Our friends at Venn Innovation in Moncton are inviting Emergence clients to participate in their upcoming Competitive Intelligence Training with Dr. Jonathan Calof.

This session is about teaching small and medium businesses how to grow by installing great processes, helping them to ask the right questions, and giving focus to their business strategy.

Jonathan Dunnett,Venn Innovation 

As a business leader, you’re bombarded by an array of issues and questions, all of which could be critical to your success.

And the ever-growing amount of data available to help you make decisions doesn’t necessarily make things easier.

How do you see through the issues and information so you can focus strategically on what will really make a difference to your organization?

Competitive Intelligence (CI) training gives you tested tools and methods that enable you to:

  • Make strategic decisions with confidence
  • Zero in on the truly crucial issues
  • Ask smarter questions
  • Collect and analyze data relevant to your questions
  • Develop processes for distributing and sharing data-driven insights
  • Anticipate change before it happens.

Beginning February 4th, Venn Innovation will be holding training that will help you make Strategic Decisions with Confidence.

This full day of training will go through the theory of competitive intelligence and then start immediately applying this to your business and one of your strategic priorities by doing a project.

Over the next month, at least once a week on your schedule, participants will receive mentorship from a global leader, Jonathan Calof, as well as local experts, to help you tackle one of your biggest strategic challenges or opportunities via your project.

This could include things such as:

  • Analyzing a new market
  • Examining competitors and how they impact your business
  • Identifying new product opportunities
  • Understanding your customer at a deeper level to increase sales
  • Identifying sales targets and building better ways to pre-qualify sales
  • Understanding upcoming regulation/legal changes and how they impact your business.

This is just a sample of potential projects you could work on through this program. The program wraps up on March 12th, which gives participants approximately 15 hours of direct contact time with the facilitator, including the mentorship period. This would be valued at over $10,000.

Early-bird pricing ends January 18th. There are no hidden costs, and this includes lunch and snacks on all training days.

Event fee (includes 2 tickets, taxes included)
Monday, February 4, 2019 from 9:00 AM to 4:30 PM
Venn Innovation, 735 Main Street, Suite 201, Moncton
$575.00 CAD

You can sign up here  or contact Jonathan Dunnett if you have any questions.

Posted in Uncategorized

Emergence client, Animal Ethics, achieves breakthrough: sheep pain relief formulation approved for human trials

A SHEEP pain relief product developed in Australia by Emergence client, Animal Ethics, has been approved for clinical trials for human use in the United Kingdom. Click here to read the full story!

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved its application for a Phase IIa clinical trial of Tri-Solfen® (for human use the product will be branded as Medi-Solfen®)  for the treatment of pain during the surgical debridement of venous leg ulcers.

Medi-Solfen® is an innovative medicine designed to  provide rapid onset and both short and prolonged analgesia effects for up to 24 hours. The topical gel contains two local anaesthetic agents and an antiseptic, and other active ingredients, designed to minimise bleeding and potentially protect against infection as well as promote healing.

The Phase IIa clinical trial will assess the safety and efficacy profile of Medi-Solfen® in providing anaesthesia when applied topically to venous leg ulcers, prior to and post-surgical debridement.  

“We are thrilled to announce the MHRA approval of our Phase IIa clinical trial design for Medi-Solfen® for the treatment of pain during the surgical debridement of venous leg ulcers. The application is based on an extensive body of evidence, which demonstrate the potential of Medi-Solfen® in providing a convenient, safe and effective method of pain mitigation in wounds and we look forward to investigating this further in venous leg ulcers, where there is a significant unmet patient need. This approval is an important milestone for Medical Ethics, with Medi-Solfen® being our first product candidate for human use progressed for clinical development and as we move towards building a proprietary wound care and pain mitigation platform.”

Allan Giffard, Managing Director of Medical Ethics

The open, randomised, parallel group-controlled study will be conducted in 90 patients in three successive stages, which aim to study the time taken to achieve surface anaesthesia, degree of post-operative pain relief and patient’s assessment of overall quality as an anaesthetic during this procedure.

Secondary objectives include the duration and quality of post-operative pain relief following a single-dose, levels of anaesthesia achieved, and influence on the early healing trajectory of the leg ulcer.

Patients with venous leg ulcers report pain to be the worst aspect of having an ulcer, especially during debridement.1-4 Pain tolerated over a long time can cause a negative mood, decreased activities of daily living, sleep disturbance, reduced mobility and social withdrawal.5 In the UK alone, there are 278,000 venous leg ulcers being treated per annum, plus an additional 420,000 leg ulcers with no specific classification, however, it is broadly accepted that a number of these are venous in origin.6

Posted in Clients, News

Emergence client, Tieös Pharmaceuticals, selected to participate in C2MP: jumpstarts next phase of development

Emergence client, Tieös Pharmaceuticals, has been selected to participate in the next C2MP cohort, and will join MATTER’s Chicago Innovation Mentors program to jumpstart their next phase of development.

Tieös Pharmaceuticals is a next-generation biotech company focused on cancer metabolic therapies. The venture has been selected to join MATTER’s Chicago Innovation Mentors (CIM) mentorship program as part of the Canada-Chicago Mentoring Program (C2MP), in collaboration with the Consulate General of Canada in Chicago

The company is one of just five selected following a competitive nationwide application process. CIM is a 6-month, team-based mentoring and scholarship program focused on science-based ventures.

CIM has helped more than 220 early stage, science-based ventures, which cumulatively have raised $200M. CIM was founded by a consortium of Chicago-area universities and industry partners in November 2010 and was acquired in January 2016 by MATTER, the life sciences/healthcare incubator hub in downtown Chicago.

“We’re excited to have Tieös take part in the C2MP program – they have a unique approach in developing oncology therapeutics with exciting potential. We are looking forward to collaborating with them to help accelerate their growth in 2019.”

Chantal Glass, Trade Commissioner, Consulate General of Canada – Chicago.

C2MP provides Tieös with the opportunity to strategically position the company for future development in the US healthcare market and provides a framework to tailor the accelerated progress of various drug development programs to the US regulatory environment and business landscape.

Arun Anand, CEO, Tieos Pharmaceuticals

“As we continue to see exciting results in our preclinical validation and development, we are thrilled to be joining CIM,” Arun Anand, CEO of Tieös told us. “The program offers an exciting opportunity for us to tailor our scientific and business development programs to the US market and positions the company well for future expansion.”

The 2019 C2MP cohort will kick off the six-month program in February 2019 with a “Day of Acceleration.” The companies will travel to MATTER in Chicago, where they will meet with MATTER member startups, partner institutions and present their ventures to the CIM mentor community.

About Tieös Pharmaceuticals
Tieös Pharmaceuticals is a privately held pre-clinical stage biotech company, focused on developing novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells. Tieös’ lead compounds in development target multiple metabolic pathways simultaneously, while utilizing intelligent drug design elements to minimize drug resistance and collateral damage to healthy and vital cells. Founded in 2016, the company has offices in Ontario and New Brunswick, Canada. For more information, visit

Posted in Clients, News